1 Guidance

1 Guidance

1.1 Lenalidomide is recommended as an option, within its marketing authorisation, that is for treating transfusion‑dependent anaemia caused by low or intermediate‑1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate, with the following condition:

  • The drug cost of lenalidomide (excluding any related costs) for people who remain on treatment for more than 26 cycles (each of 28 days; normally a period of 2 years) will be met by the company.

  • National Institute for Health and Care Excellence (NICE)